(HealthDay)—For patients with programmed death ligand 1 (PD-L1)-expressing locally advanced or metastatic non-small-cell lung cancer (NSCLC), pembrolizumab is associated with better overall survival than chemotherapy, regardless ...
Jun 4, 2018
0
4
A small study of adults with the most common form of pancreatic cancer adds to evidence that patients with BRCA1 or BRCA2 gene mutations long linked to a high risk of breast cancer have poorer overall survival rates than ...
May 17, 2018
0
180
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University ...
Apr 15, 2018
0
8
An international team of researchers led by Hassan Beyzavi of the University of Arkansas, is studying the use of platinum and gold to enable more effective forms of chemotherapy.
Mar 15, 2018
0
2
A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented ...
Dec 7, 2017
0
1
Durvalumab improves progression-free survival in patients with locally advanced, unresectable stage II lung cancer, according to late-breaking results from the phase III PACIFIC trial presented today at the ESMO 2017 Congress ...
Sep 11, 2017
0
12
Findings from a phase III clinical trial of about 300 women may introduce PARP inhibitors as a new type of treatment for breast cancer. Compared to standard chemotherapy, the oral targeted medicine olaparib (Lynparza) reduced ...
Jun 5, 2017
0
4
About one-third of patients with ovarian cancer who wouldn't be expected to respond to a PARP inhibitor had partial shrinkage of their tumor when a kinase inhibitor was added to treatment, report scientists from Dana-Farber ...
Apr 3, 2017
0
2
(HealthDay)—Zejula (niraparib) has been approved by the U.S. Food and Drug Administration to treat adult women with recurring cancers of the ovaries, fallopian tubes or abdominal wall (peritoneum) whose tumors have shrunk ...
Mar 28, 2017
0
0
(HealthDay)—For patients with advanced urothelial cancer that has recurred or progressed after platinum-based chemotherapy, pembrolizumab is associated with increased overall survival, according to a study published online ...
Feb 21, 2017
0
0
